Document Type : Original Article
Authors
- Kazem Abbaszadeh Goudarzi 1
- Sana Rahmati 2
- Maryam Nabavifard 3
- Amir Raoofi 4
- Mahdi Tadayon far 5
- Parsia Torshizi 6
- Saeideh sadat Shobeiri 7
- Mahsa Asghari 8
- Mohammad Shafi Mojadadi 9
1 Assistant Professor, Department of Medical Biotechnology, Faculty of Advanced Technologies in Medical Sciences, Golestan University of Medical Sciences, Gorgan, Iran.
2 Student, Student Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran.
3 Master, Clinical Research Development Unit, Vasei Hospital, Sabzevar University of Medical Sciences, Sabzevar, Iran.
4 Associate Professor, Department of Anatomy, Sabzevar University of Medical Sciences, Sabzevar, Iran.
5 Student Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran
6 Student Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran.
7 Assistant Professor, Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
8 Clinical Research Development Unit, Vasei Hospital, Sabzevar University of Medical Sciences, Sabzevar, Iran.
9 Associate Professor of Immunology, Department of Microbiology, Leishmaniasis Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran.
Abstract
Introduction: A third (booster) dose of the COVID-19 vaccine is strongly recommended for individuals who have completed a primary series of SARS-CoV-2 vaccination at least three months prior. This study aimed to compare the efficacy of homologous and heterologous COVID-19 booster vaccines in increasing serum anti-spike antibody levels in vaccinated individuals.
Materials and Methods: This cross-sectional study included 98 employees of Sabzevar University of Medical Sciences who had received a booster dose at least two weeks prior. Five milliliters (5 mL) of venous blood was collected from each participant, and serum anti-spike IgG concentrations were measured using an ELISA method. Participants were categorized into homologous and heterologous booster groups based on their third dose, and antibody levels were compared between the groups.
Results: No significant differences in mean serum anti-spike antibody concentrations were observed between genders or across age groups. However, the heterologous booster group demonstrated significantly higher mean anti-spike antibody levels compared to the homologous booster group. Among all vaccine types, the homologous AstraZeneca vaccine elicited significantly higher mean anti-spike antibody levels.
Conclusion: The results indicated that a heterologous booster dose elicited a stronger immune response against SARS-CoV-2 than a homologous booster, supporting its use in informed vaccination strategies.
Keywords
Main Subjects
- A Llanes, C M Restrepo, Z Caballero, S Rajeev, M A Kennedy, R Lleonart, Betacoronavirus Genomes: How Genomic Information has been Used to Deal with Past Outbreaks and the COVID-19 Pandemic. Int. J. Mol. Sci, 2020. 21.DOI: 10.3390/ijms21124546.
- M Nikolaidis, P Markoulatos, Y Van de Peer, S G Oliver, G D Amoutzias, The neighborhood of the spike gene is a hotspot for modular intertypic homologous and nonhomologous recombination in coronavirus genomes. Mol. Biol. Evol, 2022. 39. msab292.DOI: 10.1093/molbev/msab292.
- M T HOSSAIN, COVID-19 Pandemic: Animal Cross Talk and Comparison Between nSARS-CoV-2 and Animal Coronaviruses. COVID-19: Tackling Global Pandemics through Scientific and Social Tools, 2022. 15.DOI: https://doi.org/10.1016/B978-0-323-85844-1.00009-X.
- D C Angus, L Derde, F Al-Beidh, D Annane, Y Arabi, A Beane, W van Bentum-Puijk, L Berry, Z Bhimani, M Bonten, Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA, 2020. 324. 1317-1329.DOI: 10.1001/jama.2020.17022.
- M-S Mojadadi, M Mahjour, H Fahimi, A Raoofi, S S Shobeiri, Relationship between blood-based inflammatory indices and clinical score of schizophrenia patients: A cross-sectional study. Behav. Brain Res, 2024. 460. 114807.DOI: 10.1016/j.bbr.2023.114807.
- F P Polack, S J Thomas, N Kitchin, J Absalon, A Gurtman, S Lockhart, J L Perez, G Pérez Marc, E D Moreira, C Zerbini, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med, 2020. 383. 2603-2615.DOI: 10.1056/NEJMoa2034577.
- Y N Lamb, BNT162b2 mRNA COVID-19 Vaccine: First Approval. Drugs, 2021. 81. 495-501.DOI: 10.1007/s40265-021-01480-7.
- S Ahmed, S Khan, I Imran, F Al Mughairbi, F S Sheikh, J Hussain, A Khan, A Al-Harrasi, Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use. Vaccines (Basel), 2021. 9.DOI: 10.3390/vaccines9080836.
- R Shekhar, I Garg, S Pal, S Kottewar, A B Sheikh, COVID-19 vaccine booster: to boost or not to boost. Infect. Dis. Rep, 2021. 13. 924-929.DOI: https://doi.org/10.3390/idr13040084.
- Y M Bar-On, Y Goldberg, M Mandel, O Bodenheimer, L Freedman, N Kalkstein, B Mizrahi, S Alroy-Preis, N Ash, R Milo, Protection of BNT162b2 vaccine booster against Covid-19 in Israel. N. Engl. J. Med, 2021. 385. 1393-1400.DOI: https://doi.org/10.1056/nejmoa2114255.
- X Liu, R H Shaw, A S V Stuart, M Greenland, P K Aley, N J Andrews, J C Cameron, S Charlton, E A Clutterbuck, A M Collins, T Dinesh, A England, S N Faust, D M Ferreira, A Finn, C A Green, B Hallis, P T Heath, H Hill, T Lambe, R Lazarus, V Libri, F Long, Y F Mujadidi, E L Plested, S Provstgaard-Morys, M N Ramasamy, M Ramsay, R C Read, H Robinson, N Singh, D P J Turner, P J Turner, L L Walker, R White, J S Nguyen-Van-Tam, M D Snape, Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet, 2021. 398. 856-869.DOI: 10.1016/s0140-6736(21)01694-9.
- J Deng, Y Ma, Q Liu, M Du, M Liu, J Liu, Comparison of the effectiveness and safety of heterologous booster doses with homologous booster doses for SARS-CoV-2 vaccines: a systematic review and meta-analysis. Int. J. Environ. Res. Public Health, 2022. 19. 10752.DOI: https://doi.org/10.3390/ijerph191710752.
- R L Atmar, K E Lyke, M E Deming, L A Jackson, A R Branche, H M El Sahly, C A Rostad, J M Martin, C Johnston, R E Rupp, Homologous and heterologous Covid-19 booster vaccinations. N. Engl. J. Med, 2022. 386. 1046-1057.DOI: 10.1056/NEJMoa2116414.
- M Klugar, A Riad, L Mohanan, A Pokorná, COVID-19 vaccine booster hesitancy (VBH) of healthcare workers in Czechia: National cross-sectional study. Vaccines, 2021. 9. 1437.DOI: https://doi.org/10.3390/vaccines9121437.
- M-S Mojadadi, S A Javadinia, F Attarian, E Samami, M Sobhani, Anti-SARS-CoV-2 spike IgG following injection of the third dose vaccine: A systematic review with meta-analysis of heterologous versus homologous vaccination. Frontiers in Public Health, 2023. 10. 960598.DOI: https://doi.org/10.3389/fpubh.2022.960598.
- L R Baden, H M El Sahly, B Essink, K Kotloff, S Frey, R Novak, D Diemert, S A Spector, N Rouphael, C B Creech, Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med, 2021. 384. 403-416.
)